139 related articles for article (PubMed ID: 32049554)
1. How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers.
Burnier M; Kjeldsen SE; Narkiewicz K; Oparil S
Blood Press; 2020 Apr; 29(2):68-69. PubMed ID: 32049554
[No Abstract] [Full Text] [Related]
2. [Acute renal failure secondary to diarrhea due to sprue like-enteropathy associated with olmesartan].
Ulla-Rocha JL; Lopez-Piñeiro S; Puga-Gimenez M
Gastroenterol Hepatol; 2015 Oct; 38(8):514-5. PubMed ID: 25534549
[No Abstract] [Full Text] [Related]
3. Olmesartan-associated sprue-like enteropathy.
Stanich PP; Yearsley M; Meyer MM
J Clin Gastroenterol; 2013; 47(10):894-5. PubMed ID: 23751857
[No Abstract] [Full Text] [Related]
4. Olmesartan: sprue-like enteropathy.
Prescrire Int; 2016 May; 25(171):130-1. PubMed ID: 27280200
[TBL] [Abstract][Full Text] [Related]
5. Collagenous Sprue and Olmesartan: another pathological condition related to this drug.
Del Sordo R; Villanacci V; Oberti A; Moneghini D; Mocci G
Dig Liver Dis; 2021 Nov; 53(11):1524-1526. PubMed ID: 34219045
[No Abstract] [Full Text] [Related]
6. Olmesartan-Induced Enteropathy.
Adike A; Corral J; Rybnicek D; Sussman D; Shah S; Quigley E
Methodist Debakey Cardiovasc J; 2016; 12(4):230-232. PubMed ID: 28289500
[TBL] [Abstract][Full Text] [Related]
7. Sprue-like enteropathy linked to olmesartan.
Campos Ruiz A; Urtasun Arlegui L; Marra-López Valenciano C
Rev Esp Enferm Dig; 2016 May; 108(5):292-3. PubMed ID: 26925975
[TBL] [Abstract][Full Text] [Related]
8. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
Tada Y; Yagi K; Uno M; Matsushita N; Kanematsu Y; Kuwayama K; Shimada K; Nishi K; Hirasawa M; Satomi J; Kitazato KT; Kageji T; Matsuura E; Nagahiro S
J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1487-92. PubMed ID: 25891757
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan-induced enteropathy treated with budesonide.
Kempenaers S; Bogaert J; De Maeyer M; Van Hauthem P; Ramael M; Schoeters P
Acta Gastroenterol Belg; 2019; 82(2):319-321. PubMed ID: 31314195
[TBL] [Abstract][Full Text] [Related]
12. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG; Germino FW; Neutel JM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Volpe M; Brommer P; Haag U; Miele C
Clin Drug Investig; 2009; 29(1):11-25. PubMed ID: 19067471
[TBL] [Abstract][Full Text] [Related]
14. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
[TBL] [Abstract][Full Text] [Related]
15. Gastrointerestinal: Valsartan induced sprue-like enteropathy.
Soldera J; Salgado K
J Gastroenterol Hepatol; 2020 Aug; 35(8):1262. PubMed ID: 31916293
[No Abstract] [Full Text] [Related]
16. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
Maier H; Hehemann K; Vieth M
Cesk Patol; 2015; 51(2):87-8. PubMed ID: 25970720
[TBL] [Abstract][Full Text] [Related]
17. [In diarrhea of unknown origin also think of olmesartan!].
Storr M
MMW Fortschr Med; 2015 Mar; 157(4):34. PubMed ID: 25743974
[No Abstract] [Full Text] [Related]
18. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
19. [Sprue-like enteropathy due to olmesartan: a case report].
Agudo Fernández S
Gastroenterol Hepatol; 2015 Feb; 38(2):108-9. PubMed ID: 24958550
[No Abstract] [Full Text] [Related]
20. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
